GPCM
SNDX icon

Granite Point Capital Management’s Syndax Pharmaceuticals SNDX Stock Holding History

Granite Point Capital Management’s Portfolio SNDX Stock Details SNDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		– Sell
-50,000
Closed -$686K – 107
2017
Q1 		$686K Buy
+50,000
New +$519K 0.21% 56

Other funds holding SNDX

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
MAM
MPM Asset Management Boston, Massachusetts $44.5M AUM 47.28% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

Granite Point Capital Management's SNDX Position: Q2 2017 in Review

Granite Point Capital Management sold out of Syndax Pharmaceuticals (SNDX) in Q2 2017, closing a stake of 50,000 shares — an estimated $686K sold.

Granite Point Capital Management first reported a position in SNDX in Q1 2017 and held it in 1 quarter. The position peaked at $686K in Q1 2017. 66 funds tracked by Wall St. Rank hold SNDX as of Q2 2017.

  • Granite Point Capital Management reported no remaining Syndax Pharmaceuticals position as of Q2 2017 after selling out during the quarter.
  • Granite Point Capital Management sold 50,000 Syndax Pharmaceuticals shares in Q2 2017, an estimated $686K.
  • Granite Point Capital Management first reported a position in Syndax Pharmaceuticals in Q1 2017 and held it in 1 quarter.
  • Granite Point Capital Management's Syndax Pharmaceuticals position peaked at $686K in Q1 2017.
  • 66 funds tracked by Wall St. Rank held Syndax Pharmaceuticals as of Q2 2017.

Based on Granite Point Capital Management's 13F filing for Q2 2017, filed 10 Aug 2017.